Indeed, as is suggested by a recent report on combining encorafenib and cetuximab with oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) in BRAF-mutant CRC [16], the future use of the new drug combination may not be as an alternative, but as a companion to the conventional chemotherapy. The gene discussed is BRAF; the disease is colorectal carcinoma.